← Leaderboards
Ankit A Desai
University Of Chicago
$4,112,753
Attributed
$5,689,778
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $811.7K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,689,778 · 3
By mechanism
R01$5,576,962 · 2
F32$112,816 · 1
Top collaborators
- William C Nichols4 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Camron D Bryant$9,830,432
- Min-Woong Sohn$1,230,023
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsGene ExpressionReportingMediatingRegulationLinkRisk FactorsTherapeutic TargetInflammatoryCohortPublishingCessation Of LifeNovel TherapeuticsTranslatingGenomicsCoupledChronicPulmonary Arterial HypertensionMutationPathway InteractionsCandidate Disease GeneAttenuatedHypoxiaGene Targeting
Grant awards (12)
Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH Biobank$782,932
R01 · FY2025 · HL
Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH Biobank$769,444
R01 · FY2024 · HL
Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH Biobank$789,984
R01 · FY2023 · HL
Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH Biobank$811,691
R01 · FY2022 · HL
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia$461,445
R01 · FY2021 · HL · contact PI
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia$470,804
R01 · FY2020 · HL · contact PI
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia$491,668
R01 · FY2019 · HL · contact PI
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia$423,124
R01 · FY2018 · HL · contact PI
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia$69,312
R01 · FY2018 · HL · contact PI
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia$506,558
R01 · FY2017 · HL · contact PI
Genomic Studies in a Rodent Model of Pulmonary Hypertension: A Consomics Approach$59,918
F32 · FY2010 · HL · contact PI
Genomic Studies in a Rodent Model of Pulmonary Hypertension: A Consomics Approach$52,898
F32 · FY2007 · HL · contact PI